Microangiopathic Hemolytic Anemia

(Traumatic Hemolytic Anemia)

ByGloria F. Gerber, MD, Johns Hopkins School of Medicine, Division of Hematology
Reviewed/Revised Apr 2024
View Patient Education

Microangiopathic hemolytic anemia is a direct antibody test-negative intravascular hemolysis caused by excessive shear or turbulence in the circulation.

(See also Overview of Hemolytic Anemia.)

Excessive shear or turbulence in the circulation causes trauma to red blood cells (RBCs) in the peripheral blood, leading to fragmented RBCs (eg, triangles, helmet shapes) called schistocytes (see photo Schistocytes). Schistocytes are characteristic, but not specific for microangiopathic hemolytic anemia (1). Schistocytes cause a high RBC distribution width, reflecting the anisocytosis.

Microangiopathic hemolytic anemia encompasses RBC fragmentation caused by microvascular injury as well as by mechanical devices. Causes of fragmentation hemolysis include

  • Disseminated intravascular coagulation, a consumptive process secondary to other disorders such as sepsis, cancer, pregnancy complications, trauma, or surgery. Coagulation studies are abnormal with very elevated D-dimer, distinguishing disseminated intravascular coagulation from thrombotic microangiopathies

  • Stenotic or mechanical heart valves, or prosthetic valve dysfunction (ie, perivalvular leak)

  • Thrombotic thrombocytopenic purpura (TTP)

  • Hemolytic uremic syndrome (HUS—Shiga toxin or atypical/complement-mediated) or related disorders such as the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), and systemic sclerosis renal crisis

  • Rare cases of significant repetitive impact, such as foot strike hemolysis (march hemoglobinuria), karate strikes, swimming, or hand drumming

Symptoms are those of anemia and the underlying cause of the hemolytic anemia.

Treatment addresses the underlying process. Iron deficiency anemia occasionally is superimposed on the hemolysis as a result of chronic hemosiderinuria and, when present, responds to iron-replacement therapy. Keeping the hematocrit > 30 % can reduce hemolysis caused by turbulent flow in valvular hemolysis.

General reference

  1. 1. Schapkaitz E, Mezgebe MH. The Clinical Significance of Schistocytes: A Prospective Evaluation of the International Council for Standardization in Hematology Schistocyte Guidelines. Şistositlerin Klinik Önemi: Hematoloji Standardizasyon Uluslararası Komitesi Şistosit Kılavuzlarının Prospektif Bir Değerlendirmesi. Turk J Haematol 2017;34(1):59-63. doi:10.4274/tjh.2016.0359

Thrombotic Microangiopathy

Thrombotic microangiopathy (TMA) is one cause of microangiopathic hemolytic anemia. Thrombotic microangiopathies result from microvascular thrombus formation, which consume platelets and damage red blood cells, leading to ischemic organ damage. Primary thrombotic microangiopathies include the following:

TMA can also be secondary to the following:

Evidence suggests that some secondary forms of TMA may be complement-mediated (1)

TMA may also be localized to specific organs (eg, the kidney).

TMA can be confirmed by biopsy, but is usually recognized by the following:

  • Microangiopathic hemolytic anemia

  • Thrombocytopenia

  • Compatible clinical findings

When TMA is suspected, the priority is to exclude TTP, which can be rapidly fatal. If patients have diarrhea or other suggestive findings, testing for HUS is indicated. Usually the platelet count is lower in TTP and renal impairment is less profound than in AHUS; however, particularly older patients may have less classical presentations (2).

Treatment is directed at the cause. In AHUS, use of complement inhibitors can be diagnostic as well as therapeutic.

Thrombotic microangiopathy references

  1. 1. Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6(1):11-23. doi:10.1016/j.ekir.2020.10.009

  2. 2. Liu A, Dhaliwal N, Upreti H, et al. Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion 2021;61(1):266-273. doi:10.1111/trf.16188

quizzes_lightbulb_red
Test your KnowledgeTake a Quiz!
Download the free MSD Manual App iOS ANDROID
Download the free MSD Manual App iOS ANDROID
Download the free MSD Manual App iOS ANDROID